Kintara Therapeutics, Inc. (KTRA)

NASDAQ: KTRA · IEX Real-Time Price · USD
3.95
+0.31 (8.52%)
At close: Mar 21, 2023, 4:00 PM
4.14
+0.19 (4.81%)
After-hours: Mar 21, 2023, 4:54 PM EDT
8.52%
Market Cap 6.62M
Revenue (ttm) n/a
Net Income (ttm) -19.22M
Shares Out 1.68M
EPS (ttm) -14.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 14,029
Open 3.67
Previous Close 3.64
Day's Range 3.67 - 3.95
52-Week Range 2.80 - 42.00
Beta 1.00
Analysts Sell
Price Target 153.00 (+3,773.42%)
Earnings Date Feb 14, 2023

About KTRA

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 3
Stock Exchange NASDAQ
Ticker Symbol KTRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for KTRA stock is "Sell." The 12-month stock price forecast is $153.0, which is an increase of 3,773.42% from the latest price.

Price Target
$153.0
(3,773.42% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting

SAN DIEGO , March 15, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...

6 days ago - PRNewsWire

Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023

-35th Annual ROTH Conference, March 12-14, 2023 – -4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023- SAN DIEGO , March 10, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KT...

1 week ago - PRNewsWire

Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

1 month ago - PRNewsWire

Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference

SAN DIEGO , Jan. 30, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

1 month ago - PRNewsWire

Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023

SAN DIEGO , Jan. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. ( Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

2 months ago - PRNewsWire

Is Kintara Therapeutics A Hidden Gem?

Kintara Therapeutics' earnings are in the red but impressive FDA approvals could satisfy an extreme upside potential to bring them solvent by next year.

2 months ago - MarketBeat

Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday - Kintara Therapeutics (NASDAQ:KTRA)

Kintara Therapeutics Inc KTRA shares are trading higher by 24.09% to $9.94 Thursday morning after the company received FDA Orphan Drug Designation (ODD) for VAL-083.

3 months ago - Benzinga

Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

SAN DIEGO , Dec. 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

3 months ago - PRNewsWire

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

SAN DIEGO , Dec. 1, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

3 months ago - PRNewsWire

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SAN DIEGO , Nov. 30, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

3 months ago - PRNewsWire

Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer

SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

4 months ago - PRNewsWire

Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting

SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

4 months ago - PRNewsWire

Kintara Announces One-for-Fifty Reverse Stock Split

SAN DIEGO , Nov. 11, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

4 months ago - PRNewsWire

Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update

SAN DIEGO , Nov. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

4 months ago - PRNewsWire

Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study

REM-001 15-Patient Study Paused to Conserve Funds – Approximately $3 Million Saved through 2023 SAN DIEGO , Oct. 19, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "C...

5 months ago - PRNewsWire

Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update

SAN DIEGO , Sept. 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...

6 months ago - PRNewsWire

Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

6 months ago - PRNewsWire

Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer

SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

8 months ago - PRNewsWire

Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...

8 months ago - PRNewsWire

Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference

SAN DIEGO , June 21, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

9 months ago - PRNewsWire

Why Kintara Therapeutics Shares Are Skyrocketing Today

Kintara Therapeutics Inc (NASDAQ: KTRA) shares are trading higher by 28.6% to $0.24 after the FDA granted Fast Track Designation to the company's VAL-083. Fast Track is a process designed to facilitat...

9 months ago - Benzinga

Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma

SAN DIEGO , June 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

9 months ago - PRNewsWire

Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference

SAN DIEGO , June 10, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...

10 months ago - PRNewsWire

Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

SAN DIEGO , June 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

10 months ago - PRNewsWire

Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma

SAN DIEGO , May 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...

10 months ago - PRNewsWire